Linvoseltamab receives ema filing acceptance for treatment of relapsed/refractory multiple myeloma

Tarrytown, n.y., feb. 02, 2024 (globe newswire) -- regeneron pharmaceuticals, inc. (nasdaq: regn) today announced that the european medicines agency (ema) has accepted for review the marketing authorization application (maa) for linvoseltamab to treat adult patients with relapsed/refractory (r/r) multiple myeloma (mm) who have progressed after at least three prior therapies. linvoseltamab is an investigational bispecific antibody designed to bridge b-cell maturation antigen (bcma) on multiple myeloma cells with cd3-expressing t cells to facilitate t-cell activation and cancer-cell killing.
REGN Ratings Summary
REGN Quant Ranking